GoodRx Holdings Appoints Scott Wagner as Co-Chair of Board of Directors
- Scott Wagner appointed Co-Chair of GoodRx Board of Directors, effective January 21, 2025, with extensive executive experience.
- Wagner's leadership aims to enhance GoodRx's strategic vision, serving nearly 30 million consumers and over one million healthcare professionals.
- GoodRx has saved consumers over $75 billion on medications since 2011, focusing on affordable healthcare access amid leadership changes.
GoodRx Welcomes Scott Wagner as Co-Chair of Board of Directors
GoodRx Holdings, Inc., a prominent prescription savings platform in the United States, announces the appointment of Scott Wagner as Co-Chair of its Board of Directors, effective January 21, 2025. Wagner, who has been instrumental in the company’s leadership as Interim CEO from April 2023 to January 2025, brings over 25 years of executive experience to his new role. His prior tenure at GoDaddy, where he significantly expanded the company’s revenue and global reach, provides a strong foundation for his contributions to GoodRx. Alongside existing Co-Chair Trevor Bezdek, Wagner's leadership is expected to drive the strategic vision for the platform, which serves nearly 30 million consumers and over one million healthcare professionals annually.
Trevor Bezdek expressed enthusiasm for Wagner’s appointment, emphasizing his deep understanding of GoodRx's business model and the strategic initiatives he has helped to develop during his interim leadership. Wagner’s responsibilities will extend beyond his co-chair duties as he will also chair the Board's Compensation Committee. This strategic alignment of leadership comes at a critical time for GoodRx, which has established itself as a leader in providing accessible prescription savings. The company has saved consumers over $75 billion on medications since its inception in 2011, and Wagner's expertise is anticipated to further enhance operational efficiencies and service offerings.
Wagner’s appointment follows the resignation of Simon Patterson from the Board, indicating a shift in leadership dynamics at GoodRx. Patterson's departure from both the Board and its Nominating and Corporate Governance Committee opens a new chapter for the company, allowing for fresh perspectives and innovations in its governance. As GoodRx continues to expand its services in a competitive healthcare landscape, the board's composition becomes crucial to navigating regulatory challenges and enhancing consumer access to affordable medications.
In addition to its leadership changes, GoodRx remains committed to its mission of making healthcare more affordable and accessible. With partnerships across over 70,000 pharmacies nationwide, the company continues to play a vital role in the healthcare ecosystem, bridging the gap between consumers and essential medications. GoodRx encourages stakeholders to visit its investor relations website for ongoing updates and insights into its operations and future developments.